BioCentury | Jan 8, 2019
Distillery Therapeutics

Neurology

...2, 2019 doi:10.1124/jpet.118.252668 CONTACT: Norikazu Kiguchi, Wakayama Medical University, Wakayama, Japan email: kiguchi@wakayama-med.ac.jp Claire Quang Wakayama Medical University Nicotinic acetylcholine receptor alpha(4)beta(2) Pain Diabetes Wakayama...
BioCentury | May 4, 2018
Financial News

Attenua raises $35M series A

...treat ADHD. Attenua also purchased discontinued candidates TC-6987, a CHRNA7 modulator, and TC-6683, a neuronal nicotinic acetylcholine receptor alpha(4)beta(2)...
...13, 2016) . Attenua Inc., Mountain View, Calif. Jaime De Leon Attenua Inc. Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Nicotinic acetylcholine receptor alpha(4)beta(2) ATA-101 TC-5619 TC-6683 TC-6987...
BioCentury | Apr 30, 2018
Financial News

Cough company Attenua raises $35M series A, names CEO

...treat ADHD. Attenua also purchased discontinued candidates TC-6987, a CHRNA7 modulator, and TC-6683, a neuronal nicotinic acetylcholine receptor alpha(4)beta(2)...
...2016 (see BioCentury Extra, June 9, 2016) . Jaime De Leon Attenua Inc. Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Nicotinic acetylcholine receptor alpha(4)beta(2) ATA-101 TC-5619 TC-6683 TC-6987...
BioCentury | Oct 31, 2016
Company News

Catalyst Biosciences deal

Catalyst will sell TC-6499 to an undisclosed buyer for $750,000 up front and up to $37 million in milestones, plus undisclosed royalties. Catalyst, which gained the products when it merged with Targacept Inc. , declined to...
BioCentury | Aug 22, 2016
Company News

Catalyst Biosciences, Attenua deal

...granted AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) rights to develop and commercialize TC-6683, a neuronal nicotinic acetylcholine receptor alpha(4)beta(2)...
BioCentury | Apr 27, 2015
Clinical News

TC-6499: Development discontinued

...NASDAQ:TRGT), Winston-Salem, N.C. Product: TC-6499 Business: Gastrointestinal Molecular target: Nicotinic acetylcholine receptor alpha(3)beta(4) ; Nicotinic acetylcholine receptor alpha(4)beta(2)...
BioCentury | Apr 6, 2015
Company News

Catalyst Biosciences, Targacept deal

Targacept and Catalyst will merge, with Catalyst shareholders owning about 65% of the combined company and Targacept shareholders owning the remaining portion. The resulting company expects to have $40 million at closing. Targacept will provide...
BioCentury | Oct 27, 2014
Clinical News

Chantix varenicline regulatory update

...and depression vs. other smoking-cessation products (see BioCentury, Nov. 7, 2011). Pfizer markets the selective nicotinic acetylcholine receptor alpha(4)beta(2)...
BioCentury | Oct 20, 2014
Company News

Targacept, AstraZeneca deal

...gained rights to develop and commercialize AZD1446 for any indication. AZD1446 and AZD3480 are neuronal nicotinic acetylcholine receptor alpha(4)beta(2)...
BioCentury | Oct 13, 2014
Clinical News

18-methoxycoronaridine: Phase I started

Savant said partner Hebron Farmaceutica began a double-blind, placebo-controlled, Brazilian Phase I trial to evaluate oral 18-MC in healthy volunteers. Hebron is developing the compound outside of North America for leishmaniasis under an expanded material...
Items per page:
1 - 10 of 125